Metsera Inc.

The company is a clinical biopharmaceutical firm developing MET-097i as an injectable treatment for obesity in a Phase I/Phase 2 clinical trial involving overweight or obese healthy volunteers. Incorporated in Delaware, the company is focused on developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions.

Obesity and overweight are among the fastest-growing and most prevalent chronic human conditions, affecting approximately 2.5 billion people worldwide and contributing to a broad range of severe diseases. Currently approved NuSH analog peptides represent a promising treatment option for these conditions. The company utilizes its proprietary MINT peptide library of NuSH analog peptides, along with its Half-life Augmentation by Lipid Optimization (HALO) half-life extending platform and MOMENTUM oral NuSH analog peptide delivery platform, to develop highly differentiated product candidates. These candidates are being advanced into clinical trials for obesity and overweight treatment.

Headquarters

Team

Financial information